PT2906698T - Métodos para o tratamento da síndrome de alport - Google Patents
Métodos para o tratamento da síndrome de alportInfo
- Publication number
- PT2906698T PT2906698T PT137774584T PT13777458T PT2906698T PT 2906698 T PT2906698 T PT 2906698T PT 137774584 T PT137774584 T PT 137774584T PT 13777458 T PT13777458 T PT 13777458T PT 2906698 T PT2906698 T PT 2906698T
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- methods
- alport syndrome
- alport
- syndrome
- Prior art date
Links
- 208000024985 Alport syndrome Diseases 0.000 title 1
- 208000003215 hereditary nephritis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261711514P | 2012-10-09 | 2012-10-09 | |
| US201361779137P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2906698T true PT2906698T (pt) | 2019-11-05 |
Family
ID=49382663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137774584T PT2906698T (pt) | 2012-10-09 | 2013-10-08 | Métodos para o tratamento da síndrome de alport |
Country Status (34)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| MX393138B (es) | 2011-04-25 | 2025-03-24 | Sanofi Sa | Compuestos de microarn y metodos para modular la actividad de mir-21. |
| MY173600A (en) | 2012-04-25 | 2020-02-08 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| UA116639C2 (uk) * | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| WO2015061536A1 (en) | 2013-10-25 | 2015-04-30 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| JP2017532365A (ja) * | 2014-07-25 | 2017-11-02 | ゴールドフィンチ バイオファーマ，インク． | コラーゲンｉｖの置き換え |
| US10744178B2 (en) | 2014-08-21 | 2020-08-18 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention and treatment of disease |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| CN116059236A (zh) | 2015-12-14 | 2023-05-05 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
| BR112019009256A2 (pt) | 2016-11-08 | 2019-07-16 | Reata Pharmaceuticals, Inc. | métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| KR20190100225A (ko) | 2016-12-28 | 2019-08-28 | 다이이찌 산쿄 가부시키가이샤 | 알포트 증후군 치료약 |
| EP3618838A1 (en) * | 2017-05-04 | 2020-03-11 | Sanofi | Methods for treatment of alport syndrome |
| JP7227162B2 (ja) | 2017-06-06 | 2023-02-21 | ザイマージェン インコーポレイテッド | 真菌株を改良するためのｈｔｐゲノム操作プラットフォーム |
| ES2875579T3 (es) | 2017-06-06 | 2021-11-10 | Zymergen Inc | Plataforma de ingeniería genómica de HTP para mejorar Escherichia coli |
| KR20260009385A (ko) | 2017-08-25 | 2026-01-19 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| LT3700570T (lt) * | 2017-10-23 | 2025-04-10 | Stoke Therapeutics, Inc. | Priešprasmiai oligomerai, skirti būklių ir ligų, pagrįstų nonsens kodono nulemta mrnr degradacija, gydymui |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| EP3874037A4 (en) | 2018-10-31 | 2021-12-15 | Zymergen, Inc. | DETERMINIST MULTIPLEXED SET OF DNA LIBRARIES |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| WO2020185590A1 (en) | 2019-03-08 | 2020-09-17 | Zymergen Inc. | Iterative genome editing in microbes |
| WO2020185584A1 (en) | 2019-03-08 | 2020-09-17 | Zymergen Inc. | Pooled genome editing in microbes |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| US12338437B2 (en) | 2020-05-11 | 2025-06-24 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| CA3252551A1 (en) * | 2022-05-09 | 2023-11-16 | Calliditas Therapeutics Suisse Sa | NOX INHIBITORS INTENDED FOR USE IN THE TREATMENT OF ALPORT SYNDROME |
| WO2024238950A1 (en) * | 2023-05-18 | 2024-11-21 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii variants |
| CN122295113A (zh) * | 2023-11-22 | 2026-06-26 | 国立大学法人东海国立大学机构 | 囊性肾病的预防和/或治疗剂 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100574597B1 (ko) * | 1998-05-22 | 2006-04-28 | 보이스 타운 내셔널 리서치 호스피탈 | α1β1 인테그린 수용체 저해제 및 ＴＧＦ-β1 저해제의신장 질환의 치료용 용도 |
| ES2285841T3 (es) | 1998-05-22 | 2007-11-16 | Boys Town National Research Hospital | Uso de inhibidores del receptor de integrina alfa1beta1 e inhibidores de tgf-beta1 en el tratamiento de la enfermedad renal. |
| US20060008817A1 (en) | 2000-12-08 | 2006-01-12 | Invitrogen Corporation | Methods and compositions for generating recombinant nucleic acid molecules |
| EP2428570B1 (en) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| US7585501B2 (en) * | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| ITMI20032528A1 (it) * | 2003-12-19 | 2005-06-20 | Francesco Santangelo | Uso di cistina o di cisteina per la prevenzione e il |
| US7585550B2 (en) | 2004-02-02 | 2009-09-08 | College Of William And Mary | Process for modifying polymeric surfaces using deep UV irradiation |
| EP2471924A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Methods and compositions involving microRNA |
| EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| US20080187508A1 (en) | 2004-09-08 | 2008-08-07 | Boys Town National Research Hospital | Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12 |
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| US20070099196A1 (en) | 2004-12-29 | 2007-05-03 | Sakari Kauppinen | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs |
| US6995235B1 (en) | 2005-05-02 | 2006-02-07 | Univation Technologies, Llc | Methods of producing polyolefins and films therefrom |
| WO2007027894A2 (en) | 2005-08-29 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Antisense compounds having enhanced anti-microrna activity |
| EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| EA201100811A1 (ru) | 2006-04-03 | 2012-06-29 | Сантарис Фарма А/С | Фармацевтическая композиция |
| CA3042781C (en) | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| CA3144493A1 (en) | 2006-10-03 | 2008-04-10 | Arbutus Biopharma Corporation | Lipid containing formulations |
| JP2010505427A (ja) | 2006-10-09 | 2010-02-25 | ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ | 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ） |
| EP2104735A2 (en) | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| WO2008086807A2 (en) | 2007-01-19 | 2008-07-24 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
| US20100261175A1 (en) | 2007-06-15 | 2010-10-14 | Exiqon A/S | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis |
| US20080317725A1 (en) * | 2007-06-20 | 2008-12-25 | Baum Seth J | Compositions and methods of treating chronic kidney disease |
| DK2205737T3 (da) | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
| CN101980712B (zh) | 2007-10-29 | 2015-02-18 | 雷古拉斯治疗公司 | 用于肝癌治疗的靶向微小rna |
| WO2009091972A2 (en) | 2008-01-18 | 2009-07-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof |
| JP2011510678A (ja) * | 2008-02-08 | 2011-04-07 | プロセンサ ホールディング ビーブイ | Ｄｎａ反復不安定性関連遺伝性障害を治療するための方法及び手段 |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| EP2268811A1 (en) | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| JP2012518997A (ja) | 2009-02-26 | 2012-08-23 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 喫煙未経験者におけるマイクロｒｎａ、ならびに関連する材料および方法 |
| MA33488B1 (fr) | 2009-06-08 | 2012-08-01 | Miragen Therapeutics | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn |
| WO2011126842A2 (en) * | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
| MX393138B (es) | 2011-04-25 | 2025-03-24 | Sanofi Sa | Compuestos de microarn y metodos para modular la actividad de mir-21. |
| WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
| MY173600A (en) | 2012-04-25 | 2020-02-08 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| EP2864482A4 (en) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
| CN104955950B (zh) | 2012-09-26 | 2019-04-26 | 米尔克斯治疗学公司 | 具有改善的脱靶特征谱的寡核苷酸 |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
-
2013
- 2013-08-10 UA UAA201504453A patent/UA116639C2/uk unknown
- 2013-10-08 TW TW102136388A patent/TWI641388B/zh active
- 2013-10-08 KR KR1020237031594A patent/KR20230136686A/ko not_active Withdrawn
- 2013-10-08 AR ARP130103643A patent/AR092940A1/es not_active Application Discontinuation
- 2013-10-08 HR HRP20191948TT patent/HRP20191948T1/hr unknown
- 2013-10-08 DK DK13777458T patent/DK2906698T3/da active
- 2013-10-08 PL PL13777458T patent/PL2906698T3/pl unknown
- 2013-10-08 KR KR1020157009045A patent/KR102165189B1/ko active Active
- 2013-10-08 RS RS20191380A patent/RS60014B1/sr unknown
- 2013-10-08 SG SG11201502748RA patent/SG11201502748RA/en unknown
- 2013-10-08 WO PCT/US2013/063884 patent/WO2014058881A1/en not_active Ceased
- 2013-10-08 US US14/048,827 patent/US9012423B2/en active Active
- 2013-10-08 HU HUE13777458A patent/HUE045858T2/hu unknown
- 2013-10-08 CA CA2885605A patent/CA2885605A1/en active Pending
- 2013-10-08 MY MYPI2015000876A patent/MY183921A/en unknown
- 2013-10-08 NZ NZ630596A patent/NZ630596A/en not_active IP Right Cessation
- 2013-10-08 LT LT13777458T patent/LT2906698T/lt unknown
- 2013-10-08 ES ES19188663T patent/ES2960488T3/es active Active
- 2013-10-08 KR KR1020207028577A patent/KR102349184B1/ko active Active
- 2013-10-08 PT PT137774584T patent/PT2906698T/pt unknown
- 2013-10-08 KR KR1020227000173A patent/KR20220005634A/ko not_active Ceased
- 2013-10-08 UY UY35069A patent/UY35069A/es not_active Application Discontinuation
- 2013-10-08 EP EP13777458.4A patent/EP2906698B1/en active Active
- 2013-10-08 EP EP19188663.9A patent/EP3620522B1/en active Active
- 2013-10-08 JP JP2015535891A patent/JP6272880B2/ja active Active
- 2013-10-08 EA EA201590711A patent/EA201590711A1/ru unknown
- 2013-10-08 BR BR112015007709-9A patent/BR112015007709B1/pt not_active IP Right Cessation
- 2013-10-08 CN CN201380051249.9A patent/CN104718295B/zh active Active
- 2013-10-08 MX MX2015004460A patent/MX356340B/es active IP Right Grant
- 2013-10-08 ES ES13777458T patent/ES2753174T3/es active Active
- 2013-10-08 AU AU2013329427A patent/AU2013329427B2/en not_active Ceased
- 2013-10-08 SI SI201331597T patent/SI2906698T1/sl unknown
-
2015
- 2015-03-16 IL IL237768A patent/IL237768B/en active IP Right Grant
- 2015-03-16 TN TNP2015000099A patent/TN2015000099A1/fr unknown
- 2015-03-26 ZA ZA2015/02087A patent/ZA201502087B/en unknown
- 2015-04-02 US US14/677,387 patent/US9359609B2/en active Active
- 2015-04-07 CL CL2015000873A patent/CL2015000873A1/es unknown
- 2015-04-08 PH PH12015500781A patent/PH12015500781B1/en unknown
- 2015-05-07 CR CR20150236A patent/CR20150236A/es unknown
-
2016
- 2016-05-10 US US15/151,290 patent/US9688986B2/en active Active
-
2017
- 2017-05-26 US US15/606,554 patent/US9970011B2/en active Active
- 2017-12-28 JP JP2017253345A patent/JP2018080190A/ja active Pending
-
2018
- 2018-04-09 US US15/948,450 patent/US20180298385A1/en not_active Abandoned
- 2018-10-08 IL IL262200A patent/IL262200A/en unknown
-
2019
- 2019-07-29 AU AU2019210494A patent/AU2019210494A1/en not_active Abandoned
- 2019-10-16 JP JP2019189071A patent/JP2020073479A/ja active Pending
- 2019-10-30 CY CY20191101129T patent/CY1122479T1/el unknown
-
2020
- 2020-01-21 US US16/747,837 patent/US20200283765A1/en not_active Abandoned
-
2021
- 2021-07-02 US US17/366,796 patent/US20220098582A1/en not_active Abandoned
- 2021-11-18 AU AU2021269404A patent/AU2021269404A1/en not_active Abandoned
-
2022
- 2022-05-23 JP JP2022083586A patent/JP2022110140A/ja active Pending
-
2023
- 2023-07-21 US US18/356,404 patent/US20240167032A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262200A (en) | Methods for treating Alport syndrome | |
| SG11201405057YA (en) | Treatment of biomass | |
| GB201201062D0 (en) | Radiofluorination method | |
| HUE072922T2 (hu) | Ecopipam Tourette-szindróma kezelésére | |
| EP2704731A4 (en) | TREATMENT OF AVIAN ORIGIN | |
| GB201121950D0 (en) | Treatment process | |
| GB201102283D0 (en) | Treatment | |
| GB201221118D0 (en) | Methods of treatment | |
| GB201216748D0 (en) | Methods of treatment | |
| GB201216740D0 (en) | Methods of treatment | |
| GB201206330D0 (en) | Methods of treatment | |
| GB201206326D0 (en) | Methods of treatment | |
| GB201206325D0 (en) | Methods of treatment | |
| GB201206324D0 (en) | Methods of treatment | |
| GB201110602D0 (en) | Methods of treatment | |
| GB201109737D0 (en) | Methods of treatment | |
| GB201221032D0 (en) | Method of treatment | |
| GB201207894D0 (en) | Method of treatment | |
| GB201205449D0 (en) | Treatment process | |
| GB201105056D0 (en) | Treatment process | |
| GB201102284D0 (en) | Treatment | |
| GB201102265D0 (en) | Treatment | |
| GB201102273D0 (en) | Treatment | |
| GB201102266D0 (en) | Treatment | |
| GB201102268D0 (en) | Treatment |